Skip to main content
Top

Endocrine Pathology

Issue 1/2005

Content (12 Articles)

Review

Prognostic indicators in pituitary tumors

Agustinus Suhardja, Kalman Kovacs, Oded Greenberg, Bernd W. Scheithauer, Ricardo V. Lloyd

Japan EPS Proceedings

Histopathological diagnosis and prognostic factors in adrenocortical carcinoma

Motohiko Aiba, Mariko Fujibayashi

Japan EPS Proceedings

Significance of an insular component in follicular thyroid carcinoma with distant metastasis at initial presentation

Hiroto Yamashita, Yasushi Noguchi, Shiro Noguchi, Hiroyuki Yamashita, Shinya Uchino, Shinn Watanabe, Takahiro Ogawa, Tsukasa Murakami

Japan EPS Proceedings

Proposal for the histological classification of parathyroid carcinoma

Kaori Kameyama, Hiroshi Takami

Clinical Research

Expression of retinoblastoma protein in human growth hormone-secreting pituitary adenomas

Ines Donangelo, Heliomar Pereira Marcos, Paula Bruna Araújo, Jorge Marcondes, Paulo Niemeyer Filho, Mônica Gadelha, Leila Chimelli

Basic Research

Angiopoietins are expressed in the normal rat pituitary gland

Sukriti Nag, Nima Nourhaghighi, Roopa Venugopalan, Sylvia L. Asa, Duncan J. Stewart

Case Report

Pleomorphic leiomyosarcoma of the adrenal gland with osteoclast-like giant cells

Fernando A. Candanedo-González, Teresa Vela Chávez, Arturo Cérbulo-Vázquez

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine